Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2000-3-15
pubmed:abstractText
Peptides based on the complementarity-determining region 1 (CDR1) and CDR3 of an anti-DNA monoclonal antibody (mAb) carrying the 16/6 idiotype (Id) were shown to induce experimental systemic lupus erythematosus (SLE) in susceptible mouse strains. In the present study, T-cell lines specific to the pCDR1 and pCDR3 peptides were established in BALB/c and in SJL mice, respectively. The T-cell lines were characterized and analysed for their pathogenicity upon administration to syngeneic mouse strains. Both T-cell lines expressed the alphabeta T-cell receptor (TCR) and the CD4+ CD8- phenotype. Additionally, both cell lines secreted interleukin (IL)-4 and IL-10 upon stimulation with their specific peptide, thus belonged to the T helper 2 (Th2) subset. Upon immunization, the pCDR3-specific T-cell line induced experimental SLE in SJL mice. The animals produced high levels of autoimmune anti-DNA and antinuclear protein antibodies, as well as anti-16/6 Id antibodies (Abs). Furthermore, the mice developed clinical manifestations, including leukopenia, proteinuria and accumulation of immune complex deposits in their kidneys. The pCDR1-specific T-cell line failed to induce SLE when injected into BALB/c mice. It is thus suggested that pCDR3 is an immunodominant epitope in experimental SLE and that pCDR3-specific T cells initiate autoimmunity, leading to SLE, probably via epitope spreading.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-1377368, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-1478777, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-1702803, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-1916893, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-2140806, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-2272795, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-2480232, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-2659371, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-2693401, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-3086436, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-3890479, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-3919141, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-6185574, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-6974307, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-7518748, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-8268135, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-8325334, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-8548842, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-9058840, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-9114040, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-9221759, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-9223110, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-9256473, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-9457902, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-9672140, http://linkedlifedata.com/resource/pubmed/commentcorrection/10692045-9795758
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0019-2805
pubmed:author
pubmed:issnType
Print
pubmed:volume
99
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
257-65
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody.
pubmed:affiliation
Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't